Sk. Faisal Ahmed

About

Sk Faisal Ahmed, the Founder and CEO of Dawn of Bioinformatics Limited, leads the 1st Bioinformatics Company in Bangladesh. Committed to delivering a comprehensive understanding of bioinformatics, the platform serves both beginners and professionals through a diverse array of resources, including articles, tutorials, webinars, online courses, and services. Dawn of Bioinformatics is dedicated to fostering learning, facilitating discussions, and enabling networking opportunities in the field.

Beyond his work, Faisal actively engages in various activities such as debating, public speaking, and involvement in scientific clubs, and social organizations. Notably, he has been recognized with the Covid-19 Biotech Hero's Award in Bangladesh for his dedicated 1.5 years of service in a Covid lab.

Employment

• Dawn of Bioinformatics Limited Bangladesh Founder and CEO
  2024 - Present

Education

• North South University MSc in Biotechnology
  2023 - Present
• Noakhali Science and Technology University B.Sc
  2017 - 2023

Projects & Funding

Projects & funding information is unavailable.

Publications (11)

• Multi-Epitope mRNA Vaccine Targeting Dabie Bandavirus Glycoprotein: An Immunoinformatics-Based Study
  Bioinformatics and Biology Insights 2026 DOI: 10.1177/11779322261438994
  +Save
• Cheminformatics-based analysis identified Novel compounds from Nelumbo nucifera as potential inhibitors targeting PI3k/Akt/mTOR Pathway of HR+/HER2- subtype for Breast Cancer
  Biochemical and Biophysical Research Communications 2025 DOI: 10.1016/j.bbrc.2025.152953
  +Save
• In Silico Identification of Emblica officinalis Compounds Inhibiting Thermolabile Hemolysin from Vibrio alginolyticus in Shrimp
  Current Computer-Aided Drug Design 2025 DOI: 10.2174/0115734099342492250120114644
  +Save
• ‘Synthesis, antiviral activity, molecular docking, and molecular dynamics studies of ethoxy phthalimide pyrazole derivatives against Cytomegalovirus and Varicella-Zoster virus: potential consequences and strategies for developing new antiviral treatments’
  Journal of Biomolecular Structure and Dynamics 2024 DOI: 10.1080/07391102.2023.2279278
  +Save
• “In silico identification of ethoxy phthalimide pyrazole derivatives as IL-17A and IL-18 targeted gouty arthritis agents”
  Journal of Biomolecular Structure and Dynamics 2023 DOI: 10.1080/07391102.2022.2071338
  +Save
• Unlocking SGK1 inhibitor potential of bis-[1-N,7-N, pyrazolo tetraethoxyphthalimido{-4-(3,5-Dimethyl-4-(spiro-3-methylpyazolo)-1,7-dihydro-1H-dipyrazolo[3,4-b;4',3'-e]pyridin-8-yl)}]p-disubstituted phenyl compounds: a computational study
  Journal of Biomolecular Structure and Dynamics 2022 DOI: 10.1080/07391102.2021.1988711
  +Save
• Molecular docking and simulation studies of flavonoid compounds against PBP-2a of methicillin‐resistant Staphylococcus aureus
  Journal of Biomolecular Structure and Dynamics 2022 DOI: 10.1080/07391102.2021.1944911
  +Save
• Identification of novel inhibitors of high affinity iron permease (FTR1) through implementing pharmacokinetics index to fight against black fungus: An in silico approach
  Infection, Genetics and Evolution 2022 DOI: 10.1016/j.meegid.2022.105385
  +Save
• Identification of 1, 2, 4-Triazine and Its Derivatives Against Lanosterol 14-Demethylase (CYP51) Property of Candida albicans: Influence on the Development of New Antifungal Therapeutic Strategies
  Frontiers in Medical Technology 2022 DOI: 10.3389/fmedt.2022.845322
  +Save
• Identification of 1, 2, 4-triazine and its derivatives against Lanosterol 14 - demethylase (CYP51) property of Candida albicans: Influence on the development of new antifungal therapeutic strategies
  2021 DOI: 10.20944/preprints202108.0359.v1
  +Save